• Nathan Gossai, Megan V Hilgers, Lynda E Polgreen, and Emily G Greengard.
• Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota Children's Hospital, Minneapolis, Minnesota.
• Pediatr Blood Cancer. 2015 Jun 1;62(6):1078-80.

AbstractWe report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5 mg/dL (normal 8.7-10.8 mg/dL), nearly double her prior level of 8.4 mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation.© 2015 Wiley Periodicals, Inc.

17 keywords...

hide…